Evaluation of Nasal Decongestants by Literature Review

1. U.S. Food and Drug Administration. (2012). Drug applications for over-the-counter (OTC) drugs. Retrieved February 20, 2013, from http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htmSearch in Google Scholar

2. U.S. Food and Drug Administration (FDA). (2013). Over-the-Counter Medicines: What’s Right for You? Retrieved February 20, 2013, from March 09, 2013, fromSearch in Google Scholar

3. https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandingover-thecountermedicines/choosingtherightover-the-counter-medicineotcs/ucm150299.htmSearch in Google Scholar

4. Bond, C., Blenkinsopp, A. & Raynor, D. K. (2012). Prescribing and partnership with patients. British journal of clinical pharmacology. 74(4): 581-588. DOI: 10.1111/j.1365-2125.2012.04330.x.10.1111/j.1365-2125.2012.04330.xSearch in Google Scholar

5. Westerlund, T., Barzi, S. & Bernsten, C. (2017). Consumer views on safety of over-the-counter drugs, preferred retailers and information sources in Sweden: after re-regulation of the pharmacy market. Pharmacy practice. 15(1): 894. DOI: 10.1007/s11096-012-9724-1.10.1007/s11096-012-9724-1Search in Google Scholar

6. Shankar, P. R., Partha, P. & Shenoy, N. (2002). Self-medication and non-doctor prescription practices in Pokhara valley, Western Nepal: a questionnaire-based study. BMC family practice, 3, 17. DOI:10.1186/1471-2296-3-17.10.1186/1471-2296-3-17Search in Google Scholar

7. Sleath, B., Rubin, R. H., Campbell, W., Gwyther, L. & Clark. T.(2001). Physician-patient communication about over-the-counter medications. Soc Sci Med. 53(3); 357-369. PMID: 1143981910.1016/S0277-9536(00)00341-5Search in Google Scholar

8. Sansgiry, S. S., Bhansali, A. H., Bapat, S. S. & Xu, Q. (2016). Abuse of over-the-counter medicines: a pharmacist’s perspective. Integrated pharmacy research & practice. 6: 1-6. DOI:10.2147/IPRP.S103494.10.2147/IPRP.S103494Search in Google Scholar

9. Homedes, N. & Vgailde, A. (2001). Improving Use of Pharmaceuticals Through Patient and Community Level Intervention. Soc Sci Med. 52 (1): 99-134. PMID:1114492010.1016/S0277-9536(00)00131-3Search in Google Scholar

10. Parikh, D., Sattigeri, BM., Kumar, A. & Brahmbhatt, S. (2013). A survey study on use of over the counter (OTC) drugs among medical students, nursing and clerical staff of a tertiary care teaching rural hospital. Int J Res Med Sci. 1(2): 83-86. DOI: 10.5455/2320-6012.10.5455/2320-6012.ijrms20130509Search in Google Scholar

11. Zaffani, E. R., Kamimura, GF., Maniglia, AJV. & Fernades, AM. (2007) Perfil epidemiológico dos pacientes usuários de descongestionantes nasais tópicos do ambulatório de otorrinolaringologia de um hospital universitário. Arq. Ciênc. Saúde. 14(2); 95-98.Search in Google Scholar

12. Baumann, LM., Romero, KM., Robison, CL., Hansel, NN., Gilman, RH., Hamilton, RG., Lima, JJ., Wise, RA. & Checkley, W.(2015). Prevalence and risk factors for allergic rhinitis in two resource-limited settings in Peru with disparate degrees of urbanization. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 45(1): 192-9. DOI: 10.1111/cea.12379.10.1111/cea.12379533987825059756Search in Google Scholar

13. Bernstein, DI., Schwartz, G. & Bernstein, JA. (2012). Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am. 36(2): 261-78. DOI: 10.1016/j.iac.2015.12.004.10.1016/j.iac.2015.12.00427083101Search in Google Scholar

14. Corboz, M.R., Rivelli, M.A., Mingo, G.G., Mcleod, R.L., Varty, L. & Jia Y.A. (2008). Mechanism of decongestant activity of alpha 2-adrenoceptor agonists. Pul. Pharmacol. 21(3): 449-454. DOI: 10.1016/j.pupt.2007.06.007.10.1016/j.pupt.2007.06.00717869148Search in Google Scholar

15. Doshi, J. (2009). Rhinitis medicamentosa: what an otolaryngologist needs to know. Eur. Arch. Otorhinolaryngol. 266(5): 623-625. DOI:10.1007/s00405-008-0896-1.10.1007/s00405-008-0896-119096862Search in Google Scholar

16. Servidoni, AB., Coelho, L., Navarro, ML., Ávila, FG. & Mezzalira R. (2006). Perfil da automedicação nos pacientes otorrinolaringológicos. Rev. Bras. Otorrinolaringol. 72(1): 83-88. DOI: org/10.1590/S0034-72992006000100013.10.1590/S0034-72992006000100013Search in Google Scholar

17. Lenz, D., Cardoso, KS., Bitti, AC. & Andrade, TU. (2011). Evaluation of the use of topic nasal decongestants in university students from health sciences courses. Brazilian Journal of Pharmaceutical Sciences. 47(4): 761-767. DOI: org/10.1590/S1984-82502011000400013.10.1590/S1984-82502011000400013Search in Google Scholar

18. Eccles, R., Eriksson, M., Garreffa, S. & Chen. SC. (2008). The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology. 22(5): 491-496. DOI: 10.2500/ajr.2008.22.3202.10.2500/ajr.2008.22.3202Search in Google Scholar

19. Lui, CT. (2017). Prescription practice of antihistamines for acute upper respiratory tract infections in pediatric patients in a local emergency department in Hong Kong. World J Emerg Med. 8(1): 47-54. DOI: 10.5847/wjem.j.1920-8642.10.5847/wjem.j.1920-8642.2017.01.009Search in Google Scholar

20. Zeynettin, K. & Abdullah, T., (2013). Adverse Cardiac Effects of Decongestant Agents. Eur J Gen Med. 10(1): 32-35. DOI: https://doi.org/10.29333/ejgm/8230110.29333/ejgm/82301Search in Google Scholar

21. ANSM - Juillet 2013. Plan d’action sur les médicaments contenant des vasoconstricteurs à visée décongestionnante. Retrieved ANSM - Juillet 2013, from https://ansm.sante.fr/var/ansm_site/storage/original/application/c6285e0a4e1f950eaa262d4d788f134c.pdfSearch in Google Scholar

22. Hallas, J., Bjerrum, L. Stovring, H. & Andersen, M. (2008). Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol. 168(8): 966-73. DOI: 10.1093/aje/kwn191.10.1093/aje/kwn191Search in Google Scholar

23. Stewart, M., Ferguson, B. & Fromer, L. (2010). Epidemiology and burden of nasal congestion. International journal of general medicine. 3: 37-45. Published 2010 Apr 8.10.2147/IJGM.S8077Search in Google Scholar

24. Mortuaire,G., de Gabory L., François, M., Massé, G., Bloch, F., Brion, N., Jankowski R. & Serrano, E. (2013). Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 130(3): 137-144. doi: 10.1016/j.anorl.2012.09.005.10.1016/j.anorl.2012.09.005Search in Google Scholar

25. Eccles R. (2006). Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse. British journal of clinical pharmacology. 63(1): 10-4. DOI: 10.1111/j.1365-2125.2006.02833.x10.1111/j.1365-2125.2006.02833.xSearch in Google Scholar

26. Eccles, R., Martensson, K. & Chen, SC. (2010). Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Curr Med Res Opin. 26(4): 889-99. DOI: 10.1185/03007991003648015.10.1185/03007991003648015Search in Google Scholar

27. Mortuaire, G., de Gabory, L., François, M., Massé, G., Bloch, F., Brion, N., Jankowski, R.& Serrano.E. (2013). Effet rebond et rhinite aux vasoconstricteurs nasaux en pratique clinique. Revue critique de la littérature par un groupe d’experts. Annales Françaises d’Oto-Rhino-Laryngologie et de pathologie cervico-faciale. 130 (3): 140-148. Doi : 10.1016/j.aforl.2012.11.007.10.1016/j.aforl.2012.11.007Search in Google Scholar

28. Eccles, R., Jawad, MS., Jawad, SS., Angello, JT. & Druce, HM. (2005). Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. Am J Rhinol. 19(1): 25-31. DOI:10.1177/194589240501900105.10.1177/194589240501900105Search in Google Scholar

29. ANSM. Commission Nationale de Pharmacovigilance du 20 novembre 2012. http://www.ansm.sante.fr/var/ansm_site/storage/original/application/c9e15dee904acc094f9b909eea1634a2.pdfSearch in Google Scholar

30. Nathan, R.A., Finn AF Jr., La Force, C., Ratner, P., Chapman, D., de Guia, EC., Hewlett, D. & Kramer, B. (2006). Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. Ann Allergy Asthma Immunol. 97(3): 389-396. DOI: 10.1016/S1081-1206(10)60806-X.10.1016/S1081-1206(10)60806-XSearch in Google Scholar

31. Browning, MG., Seddon, JO., Yung, LT. & Gough, G. (2011). An unusual case of systemic cardiovascular side effects from the application of over-the-counter nasal de-congestion drops. BMJ Case Rep. 2011; 2011:bcr0620103078. Published 2011 Mar 24. DOI: 10.1136/bcr.06.2010.3078.Search in Google Scholar

32. Rimsza, M.E. & Newberry, S. (2008). Unexpected infant deaths associated with use of cough and cold medications. Pediatrics. 122(2): 318-322. DOI: 10.1542/peds.2007-3813.10.1542/peds.2007-381318676517Search in Google Scholar

33. Abood, E. A., Scott, J., & Wazaify, M. (2018). User Experiences of Prescription and Over-The-Counter Drug Abuse in Aden City, Yemen. Pharmacy (Basel, Switzerland), 6(3): 99. DOI:10.3390/pharmacy6030099.10.3390/pharmacy6030099616521230217022Search in Google Scholar

34. Laccourreye, O., Werner, A., Giroud, J.P., Couloigner, V., Bonfils, P. & Emmanuelle Bondon-Guitton. (2015). Apport, dangers et limites de l’éphédrine et de la pseudoéphédrine en tant que décongestionnant nasal. Annales françaises d’Oto-rhino-laryngologie et de Pathologie Cervico-faciale. 132(1): 28-31. DOI: 10.1016/j.aforl.2014.11.007.10.1016/j.aforl.2014.11.007Search in Google Scholar

35. Atkinson, HC., Stanescu, I. & Anderson, BJ.(2014). Increased phenylephrine plasma levels with administration of acetaminophen. N Eng J Med. 370(12): 1171-1172. doi: 10.1056/NEJMc1313942.10.1056/NEJMc1313942Search in Google Scholar

36. Vaidyanathan, S., Williamson, P., Clearie, K., Khan, F. & Lipworth, B.(2010). Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of Response and Rebound Congestion. 182 (1); 19-24. DOI: 10.1164/rccm.200911-1701OC.10.1164/rccm.200911-1701OCSearch in Google Scholar

37. Pray SW, Pray JJ. Safe Use of Nasal Decongestants. US Pharmacist. 2004;29(7).Search in Google Scholar

38. Fabi, M., Formigari, R. & Picchio FM. (2009). Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope. Cardiol Young. 19: 633-634. DOI: 10.1017/S1047951109990722.10.1017/S1047951109990722Search in Google Scholar

39. Dokuyucu, R., Gokce, H., Sahan, M., Sefil, F., Tas, ZA., Tutuk, O., Ozturk. A., Tumer, C. & Cevik, C. (2015). Systemic side effects of locally used oxymetazoline. Int J Clin Exp Med. 8 (2): 2674-2678. Published online 2015 Feb 15.Search in Google Scholar

40. Antonicelli, L., Micucci, C., Voltolini, S., Senna, GE., Di Blasi, P., Visonà, G., De Marco, R. & Bonifazi F. (2007). Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. Clin Exp Allergy. 62(9): 1064-1070. DOI: 10.1111/j.1398-9995.2007.01470.x10.1111/j.1398-9995.2007.01470.xSearch in Google Scholar

41. Giavina-Bianchi, P., Agondi, R., Stelmach, R., Cukier, A. & J.Kalil. (2008). Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Ther Clin Risk Manag. 4(2): 465-472.10.2147/TCRM.S1984Search in Google Scholar

42. Martin, BG., Ratner, PH., Hampel, FC., Andrews, CP., Toler, T., Wu, W., Faris, MA. & Philpot, EE. (2007). Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 28 (2): 216-225. DOI: https://doi.org/10.2500/aap.2007.28.298310.2500/aap.2007.28.2983Search in Google Scholar

43. Hampel, FC. Jr, Jacobs, R., Martin, B., Toler, T., Ellsworth, A. & Philpot, E. (2007). Once-daily fluticasone furoate nasal spray (FF) provides 24-hour symptom relief in subjects with seasonal allergic rhinitis (SAR) caused by mountain cedar pollen. J Allergy Clin Immunol. 119(1): 304-5. DOI:https://doi.org/10.1016/j.jaci.2006.12.56310.1016/j.jaci.2006.12.563Search in Google Scholar

44. Juel-Berg, N., Darling, P., Bolvig, J.,Foss-Skiftesvik, MH., Halken, S. &Winther, L.(2017). Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy. 31(1): 19-28. DOI: 10.2500/ajra.2016.30.4397.10.2500/ajra.2016.30.4397Search in Google Scholar

45. Meltzer, EO. (2007). Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 98(1); 12-21. DOI: 10.1016/S1081-1206(10)60854-X.10.1016/S1081-1206(10)60854-XSearch in Google Scholar

46. Verret, DJ. & Marple, BF.(2005). Effect of topical nasal steroid sprays on nasal mucosa and ciliary function. Curr Opin Otolaryngol Head Neck Surg. 13(1): 14-18.10.1097/00020840-200502000-00005Search in Google Scholar

47. Riechelmann, H., Deutschle, T., Stuhlmiller, A., Gronau, S. & Bürner, H. (2004). Nasal toxicity of benzalkonium chloride. Am J Rhinol. 18(5): 291-299. https://doi.org/10.1177/19458924040180050610.1177/194589240401800506Search in Google Scholar

48. Peter, Graf. & Hans, Hallén. (1996). Effect on the Nasal Mucosa of Long Term Treatment With Oxymetazoline, Benzalkonium Chloride, and Placebo Nasal Sprays. The Laryngoscope. 106 (5 Pt 1), 605-609. DOI:10.1097/00005537-199605000-00016.10.1097/00005537-199605000-00016Search in Google Scholar

49. Dimova, S., Mugabowindekwe, R., Willems, T. Brewster, ME., Noppe, M., Ludwig, A., Jorissen, M., Augustijns, P. (2003). Safety-assessment of 3-methoxyquercetin as an anthirhinoviral compund for nasal application: effect on ciliary beat frequency. Int J Pharm. 263(1): 95-103.10.1016/S0378-5173(03)00363-6Search in Google Scholar

50. Meltzer, EO. (2007). Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 98(1): 12-21. DOI: 10.1016/S1081-1206(10)60854-X.10.1016/S1081-1206(10)60854-XSearch in Google Scholar

51. Oppliger, R. & Hauser, C. (2004). Anaphylaxis after injection of corticosteroid preparations-carboxymethyl-cellulose as a hidden allergen [in German]. J Dtsch Dermatol Ges. 2(11): 928-930.Search in Google Scholar

52. Kirtsreesakul, V., Wongsritrang, K. & Ruttanaphol, S. (2011). Clinical efficacy of a short course of systemic steroids in nasal polyposis. Rhinology. 49(5): 525-532.10.4193/Rhino11.140Search in Google Scholar

53. DOI: 10.4193/Rhino11.140.10.4193/Rhino11.14022125782Search in Google Scholar

54. Vaidyanathan, S., Barnes, M., Williamson, P., Hopkinson, P., Donnan, P.T. & Lipworth, B. (2011). Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: A randomized trial. Ann Intern Med. 154 (5): 293-302. DOI: 10.7326/0003-4819-154-5-201103010-00003.10.7326/0003-4819-154-5-201103010-0000321357906Search in Google Scholar

55. Sastre, J. & Mosges, R. (2012). Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 22(1): 1-12.Search in Google Scholar